---
figid: PMC6695603__ijms-20-03821-g002
figtitle: PD-1/PD-L1 immune checkpoint in NSCLC
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6695603
filename: ijms-20-03821-g002.jpg
figlink: /pmc/articles/PMC6695603/figure/ijms-20-03821-f002/
number: F2
caption: PD-1/PD-L1 immune checkpoint in NSCLC. In NSCLC cells, the binding of PD-1
  and PD-L1 promotes T-cell tolerance and escape from host immunity. Immunotherapy
  targeting the PD-1/PD-L1 immune checkpoints has used to treat metastatic NSCLC.
  Pembrolizumab, nivolumab and cemiplimab are anti-PD-1 inhibitors, and atezolizumab,
  durvalumab and avelumab are anti-PD-L1 inhibitors.
papertitle: Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein
  (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell
  Lung Cancer (NSCLC).
reftext: Ping-Chih Hsu, et al. Int J Mol Sci. 2019 Aug;20(15):3821.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9344178
figid_alias: PMC6695603__F2
figtype: Figure
redirect_from: /figures/PMC6695603__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6695603__ijms-20-03821-g002.html
  '@type': Dataset
  description: PD-1/PD-L1 immune checkpoint in NSCLC. In NSCLC cells, the binding
    of PD-1 and PD-L1 promotes T-cell tolerance and escape from host immunity. Immunotherapy
    targeting the PD-1/PD-L1 immune checkpoints has used to treat metastatic NSCLC.
    Pembrolizumab, nivolumab and cemiplimab are anti-PD-1 inhibitors, and atezolizumab,
    durvalumab and avelumab are anti-PD-L1 inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - HLA-C
  - TCR
  - NSCLC tumor
---
